This company has been marked as potentially delisted and may not be actively trading.

LakeShore Biopharma (LSB) Competitors

LSB vs. ANVS, PDSB, ATOS, TELO, and IXHL

Should you be buying LakeShore Biopharma stock or one of its competitors? The main competitors of LakeShore Biopharma include Annovis Bio (ANVS), PDS Biotechnology (PDSB), Atossa Genetics (ATOS), Telomir Pharmaceuticals (TELO), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does LakeShore Biopharma compare to Annovis Bio?

LakeShore Biopharma (NASDAQ:LSB) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

: In the previous week, Annovis Bio's average media sentiment score of 0.97 beat LakeShore Biopharma's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media.
Company Overall Sentiment
LakeShore Biopharma Neutral
Annovis Bio Positive
: LakeShore Biopharma's return on equity of 0.00% beat Annovis Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
LakeShore Biopharma N/A N/A N/A
Annovis Bio N/A -159.43% -133.49%
: LakeShore Biopharma has higher revenue and earnings than Annovis Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LakeShore Biopharma $85.67M 0.15 -$13.93M N/A N/A
Annovis Bio N/A N/A -$28.85M -$1.40 N/A
: Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 491.07%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than LakeShore Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Annovis Bio
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: 52.6% of LakeShore Biopharma shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Company	Overall Sentiment
LakeShore Biopharma	Neutral
Annovis Bio	Positive

Company	Net Margins	Return on Equity	Return on Assets
LakeShore Biopharma	N/A	N/A	N/A
Annovis Bio	N/A	-159.43%	-133.49%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LakeShore Biopharma	$85.67M	0.15	-$13.93M	N/A	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LakeShore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Annovis Bio beats LakeShore Biopharma on 6 of the 11 factors compared between the two stocks.

How does LakeShore Biopharma compare to PDS Biotechnology?

LakeShore Biopharma (NASDAQ:LSB) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

: PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 749.06%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than LakeShore Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
PDS Biotechnology
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, PDS Biotechnology had 2 more articles in the media than LakeShore Biopharma. MarketBeat recorded 2 mentions for PDS Biotechnology and 0 mentions for LakeShore Biopharma. PDS Biotechnology's average media sentiment score of 0.96 beat LakeShore Biopharma's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media.
Company Overall Sentiment
LakeShore Biopharma Neutral
PDS Biotechnology Positive
: LakeShore Biopharma has higher revenue and earnings than PDS Biotechnology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LakeShore Biopharma $85.67M 0.15 -$13.93M N/A N/A
PDS Biotechnology N/A N/A -$34.50M -$0.75 N/A
: LakeShore Biopharma's return on equity of 0.00% beat PDS Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
LakeShore Biopharma N/A N/A N/A
PDS Biotechnology N/A -241.95% -90.36%
: 52.6% of LakeShore Biopharma shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: LakeShore Biopharma has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LakeShore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
LakeShore Biopharma	Neutral
PDS Biotechnology	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LakeShore Biopharma	$85.67M	0.15	-$13.93M	N/A	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
LakeShore Biopharma	N/A	N/A	N/A
PDS Biotechnology	N/A	-241.95%	-90.36%

Summary

PDS Biotechnology beats LakeShore Biopharma on 7 of the 12 factors compared between the two stocks.

How does LakeShore Biopharma compare to Atossa Genetics?

LakeShore Biopharma (NASDAQ:LSB) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

: LakeShore Biopharma's return on equity of 0.00% beat Atossa Genetics' return on equity.
Company Net Margins Return on Equity Return on Assets
LakeShore Biopharma N/A N/A N/A
Atossa Genetics N/A -65.56% -57.74%
: 52.6% of LakeShore Biopharma shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: LakeShore Biopharma has higher revenue and earnings than Atossa Genetics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LakeShore Biopharma $85.67M 0.15 -$13.93M N/A N/A
Atossa Genetics N/A N/A -$34.77M -$3.60 N/A
: In the previous week, Atossa Genetics had 2 more articles in the media than LakeShore Biopharma. MarketBeat recorded 2 mentions for Atossa Genetics and 0 mentions for LakeShore Biopharma. LakeShore Biopharma's average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.
Company Overall Sentiment
LakeShore Biopharma Neutral
Atossa Genetics Neutral
: Atossa Genetics has a consensus price target of $36.33, indicating a potential upside of 551.14%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than LakeShore Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Atossa Genetics
2 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.40
: LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
LakeShore Biopharma	N/A	N/A	N/A
Atossa Genetics	N/A	-65.56%	-57.74%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LakeShore Biopharma	$85.67M	0.15	-$13.93M	N/A	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.60	N/A

Company	Overall Sentiment
LakeShore Biopharma	Neutral
Atossa Genetics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LakeShore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Atossa Genetics beats LakeShore Biopharma on 7 of the 12 factors compared between the two stocks.

How does LakeShore Biopharma compare to Telomir Pharmaceuticals?

LakeShore Biopharma (NASDAQ:LSB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

: In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than LakeShore Biopharma. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for LakeShore Biopharma. LakeShore Biopharma's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
LakeShore Biopharma Neutral
Telomir Pharmaceuticals Neutral
: 52.6% of LakeShore Biopharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Telomir Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: LakeShore Biopharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
LakeShore Biopharma N/A N/A N/A
Telomir Pharmaceuticals N/A -315.26% -259.29%
: LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500.
: Telomir Pharmaceuticals has lower revenue, but higher earnings than LakeShore Biopharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LakeShore Biopharma $85.67M 0.15 -$13.93M N/A N/A
Telomir Pharmaceuticals N/A N/A -$10.41M -$0.33 N/A

Company	Overall Sentiment
LakeShore Biopharma	Neutral
Telomir Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LakeShore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
LakeShore Biopharma	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LakeShore Biopharma	$85.67M	0.15	-$13.93M	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A

Summary

LakeShore Biopharma beats Telomir Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does LakeShore Biopharma compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

: LakeShore Biopharma has higher revenue and earnings than Incannex Healthcare.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incannex Healthcare $90K 629.64 -$46.88M -$8.41 N/A
LakeShore Biopharma $85.67M 0.15 -$13.93M N/A N/A
: In the previous week, Incannex Healthcare's average media sentiment score of 0.00 equaled LakeShore Biopharma'saverage media sentiment score.
Company Overall Sentiment
Incannex Healthcare Neutral
LakeShore Biopharma Neutral
: LakeShore Biopharma's return on equity of 0.00% beat Incannex Healthcare's return on equity.
Company Net Margins Return on Equity Return on Assets
Incannex Healthcare N/A -114.95% -103.38%
LakeShore Biopharma N/A N/A N/A
: Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
LakeShore Biopharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	629.64	-$46.88M	-$8.41	N/A
LakeShore Biopharma	$85.67M	0.15	-$13.93M	N/A	N/A

Company	Overall Sentiment
Incannex Healthcare	Neutral
LakeShore Biopharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
LakeShore Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LakeShore Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

LakeShore Biopharma beats Incannex Healthcare on 5 of the 9 factors compared between the two stocks.

Get LakeShore Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSB vs. The Competition

Export

Metric	LakeShore Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.02M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	38.57	29.25	27.07
Price / Sales	0.15	280.02	504.68	73.47
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.19	7.05	9.67	6.69
Net Income	-$13.93M	$23.62M	$3.55B	$332.64M

LakeShore Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSB LakeShore Biopharma	N/A	$0.63 flat	N/A	N/A	$13.02M	$85.67M	N/A	773
ANVS Annovis Bio	3.1337 of 5 stars	$1.75 +0.7%	$13.50 +670.1%	N/A	$51.31M	N/A	N/A	3
PDSB PDS Biotechnology	3.1258 of 5 stars	$0.90 flat	$9.00 +899.4%	N/A	$50.27M	N/A	N/A	20	Gap Up
ATOS Atossa Genetics	2.0033 of 5 stars	$5.70 flat	$36.33 +537.4%	N/A	$49.08M	N/A	N/A	8	News Coverage Upcoming Earnings
TELO Telomir Pharmaceuticals	N/A	$1.40 flat	N/A	N/A	$48.13M	N/A	N/A	1

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LakeShore Biopharma (LSB) Competitors

LSB vs. ANVS, PDSB, ATOS, TELO, and IXHL

How does LakeShore Biopharma compare to Annovis Bio?

Summary

How does LakeShore Biopharma compare to PDS Biotechnology?

Summary

How does LakeShore Biopharma compare to Atossa Genetics?

Summary

How does LakeShore Biopharma compare to Telomir Pharmaceuticals?

Summary

How does LakeShore Biopharma compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSB vs. The Competition

LakeShore Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LakeShore Biopharma (LSB) Competitors

LSB vs. ANVS, PDSB, ATOS, TELO, and IXHL

How does LakeShore Biopharma compare to Annovis Bio?

Summary

How does LakeShore Biopharma compare to PDS Biotechnology?

Summary

How does LakeShore Biopharma compare to Atossa Genetics?

Summary

How does LakeShore Biopharma compare to Telomir Pharmaceuticals?

Summary

How does LakeShore Biopharma compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSB vs. The Competition

LakeShore Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools